Kairos Pharma, Ltd.
KAPA
$1.08
-$0.06-5.26%
| Weiss Ratings | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 17.21% | |||
| 30-Day Total Return | -5.26% | |||
| 60-Day Total Return | 11.34% | |||
| 90-Day Total Return | -36.47% | |||
| Year to Date Total Return | -29.41% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -71.50% | |||
| 52-Week Low % Change | 34.02% | |||
| Price | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.00 | |||
| 52-Week Low Price | $0.85 | |||
| 52-Week Low Price (Date) | Mar 10, 2025 | |||
| 52-Week High Price (Date) | Sep 16, 2024 | |||
| Valuation | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 15.62M | |||
| Enterprise Value | 12.54M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.26 | |||
| Earnings Per Share Growth | 198.26% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 4.39 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.08 | |||
| Enterprise Value/EBITDA (TTM) | -6.89 | |||
| Enterprise Value/EBIT | -6.33 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 10.91M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 310-948-2356 | |||
| Address | 2355 Westwood Boulevard Los Angeles, CA 90064 | |||
| Website | kairospharma.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -41.60% | |||
| Return on Equity | -- | |||
| Income Statement | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -1.82M | |||
| EBIT (TTM) | -1.98M | |||
| Net Income (TTM) | -2.74M | |||
| Net Income Avl. to Common (TTM) | -2.74M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -235.58% | |||
| EPS Diluted (TTM) | -0.26 | |||
| EPS Diluted Growth (Q YOY) | -217.88% | |||
| Balance Sheet | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.22M | |||
| Cash Per Share (Q) | $0.29 | |||
| Total Current Assets (Q) | 4.74M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 3.33M | |||
| Current Ratio (Q) | 2.836 | |||
| Book Value Per Share (Q) | $0.26 | |||
| Total Assets (Q) | 5.00M | |||
| Total Current Liabilities (Q) | 1.67M | |||
| Total Debt (Q) | 142.00K | |||
| Total Liabilities (Q) | 1.67M | |||
| Total Common Equity (Q) | 3.33M | |||
| Cash Flow | KAPA - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 5.20M | |||
| Net Change in Cash (TTM) | 3.12M | |||
| Levered Free Cash Flow (TTM) | -3.52M | |||
| Cash from Operations (TTM) | -2.09M | |||
